{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T02:56:44Z","timestamp":1790996204256,"version":"4.1.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,22]],"date-time":"2022-04-22T00:00:00Z","timestamp":1650585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,22]],"date-time":"2022-04-22T00:00:00Z","timestamp":1650585600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"crossref","award":["BX00336"],"award-info":[{"award-number":["BX00336"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"crossref","award":["BX00336"],"award-info":[{"award-number":["BX00336"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Interferon-\u03b3 (IFN\u03b3) is a cytokine with limited evidence of benefit in cancer clinical trials to date. However, it could potentially play a role in potentiating anti-tumor immunity in the immunologically \"cold\" metastatic castration-resistant prostate cancer (mCRPC) by inducing antigen presentation pathways and concurrently providing targets for immune checkpoint blockade therapy. Moreover, it could additionally increase sensitivity to chemotherapy based on its pleiotropic effects on cell phenotype. Here, we show that IFN\u03b3 treatment induced expression of major histocompatibility class-I (MHC-I) genes and PD-L1 in prostate cancer cells in vitro. Furthermore, IFN\u03b3 treatment led to a decrease in E-cadherin expression with a consequent increase in sensitivity to chemotherapy in vitro. In an in vivo murine tumor model of spontaneous metastatic prostate cancer, IFN\u03b3 systemic pretreatment upregulated the expression of HLA-A and decreased E-cadherin expression in the primary tumor, and more importantly in the metastatic site led to increased apoptosis and limited micrometastases in combination with paclitaxel treatment compared to diffuse metastatic disease in control and monotherapy treatment groups. These findings suggest that IFN\u03b3 may be useful in combinatorial regimens to induce sensitivity to immunotherapy and chemotherapy in hepatic metastases of mCRPC.<\/jats:p>","DOI":"10.1038\/s41598-022-10724-9","type":"journal-article","created":{"date-parts":[[2022,4,22]],"date-time":"2022-04-22T11:03:30Z","timestamp":1650625410000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Interferon-\u03b3 increases sensitivity to chemotherapy and provides immunotherapy targets in models of metastatic castration-resistant prostate cancer"],"prefix":"10.1038","volume":"12","author":[{"given":"Dimitrios","family":"Korentzelos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1637-8150","authenticated-orcid":false,"given":"Alan","family":"Wells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1590-2560","authenticated-orcid":false,"given":"Amanda M.","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,22]]},"reference":[{"issue":"8","key":"10724_CR1","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1158\/2326-6066.CIR-18-0940","volume":"7","author":"S Zhang","year":"2019","unstructured":"Zhang, S. et al. Systemic Interferon-gamma increases MHC class I expression and T-cell infiltration in cold tumors: results of a phase 0 clinical Trial. Cancer Immunol. Res. 7(8), 1237\u20131243 (2019).","journal-title":"Cancer Immunol. Res."},{"issue":"9","key":"10724_CR2","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/s41577-018-0029-z","volume":"18","author":"LB Ivashkiv","year":"2018","unstructured":"Ivashkiv, L. B. IFNgamma: signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy. Nat. Rev. Immunol. 18(9), 545\u2013558 (2018).","journal-title":"Nat. Rev. Immunol."},{"issue":"10","key":"10724_CR3","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1158\/1078-0432.CCR-16-0224","volume":"22","author":"M Mandai","year":"2016","unstructured":"Mandai, M. et al. Dual faces of IFNgamma in cancer progression: a role of PD-L1 induction in the determination of pro- and antitumor immunity. Clin. Cancer Res. 22(10), 2329\u20132334 (2016).","journal-title":"Clin. Cancer Res."},{"issue":"6832","key":"10724_CR4","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1038\/35074122","volume":"410","author":"V Shankaran","year":"2001","unstructured":"Shankaran, V. et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410(6832), 1107\u20131111 (2001).","journal-title":"Nature"},{"issue":"2","key":"10724_CR5","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.cell.2016.08.069","volume":"167","author":"J Gao","year":"2016","unstructured":"Gao, J. et al. Loss of IFN-gamma pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy. Cell. 167(2), 397-404 e399 (2016).","journal-title":"Cell."},{"issue":"8","key":"10724_CR6","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1172\/JCI91190","volume":"127","author":"M Ayers","year":"2017","unstructured":"Ayers, M. et al. IFN-gamma-related mRNA profile predicts clinical response to PD-1 blockade. J. Clin. Invest. 127(8), 2930\u20132940 (2017).","journal-title":"J. Clin. Invest."},{"issue":"7669","key":"10724_CR7","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/nature23477","volume":"548","author":"SJ Patel","year":"2017","unstructured":"Patel, S. J. et al. Identification of essential genes for cancer immunotherapy. Nature 548(7669), 537\u2013542 (2017).","journal-title":"Nature"},{"issue":"7664","key":"10724_CR8","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/nature23270","volume":"547","author":"RT Manguso","year":"2017","unstructured":"Manguso, R. T. et al. In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target. Nature 547(7664), 413\u2013418 (2017).","journal-title":"Nature"},{"issue":"1\u20132","key":"10724_CR9","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.cell.2014.12.033","volume":"160","author":"MS Rooney","year":"2015","unstructured":"Rooney, M. S. et al. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 160(1\u20132), 48\u201361 (2015).","journal-title":"Cell"},{"issue":"4","key":"10724_CR10","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1158\/0008-5472.CAN-15-3142","volume":"77","author":"X Wang","year":"2017","unstructured":"Wang, X. et al. Suppression of type I IFN signaling in tumors mediates resistance to anti-PD-1 treatment that can be overcome by radiotherapy. Cancer Res. 77(4), 839\u2013850 (2017).","journal-title":"Cancer Res."},{"issue":"3\u20134","key":"10724_CR11","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1080\/08830180902978120","volume":"28","author":"F Zhou","year":"2009","unstructured":"Zhou, F. Molecular mechanisms of IFN-gamma to up-regulate MHC class I antigen processing and presentation. Int. Rev. Immunol. 28(3\u20134), 239\u2013260 (2009).","journal-title":"Int. Rev. Immunol."},{"issue":"2","key":"10724_CR12","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1158\/2159-8290.CD-16-1223","volume":"7","author":"DS Shin","year":"2017","unstructured":"Shin, D. S. et al. Primary resistance to PD-1 blockade mediated by JAK1\/2 mutations. Cancer Discov. 7(2), 188\u2013201 (2017).","journal-title":"Cancer Discov."},{"key":"10724_CR13","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.3389\/fimmu.2018.01786","volume":"9","author":"AR Elia","year":"2018","unstructured":"Elia, A. R., Caputo, S. & Bellone, M. Immune checkpoint-mediated interactions between cancer and immune cells in prostate adenocarcinoma and melanoma. Front. Immunol. 9, 1786 (2018).","journal-title":"Front. Immunol."},{"issue":"26","key":"10724_CR14","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian, S. L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366(26), 2443\u20132454 (2012).","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10724_CR15","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1093\/annonc\/mdy232","volume":"29","author":"AR Hansen","year":"2018","unstructured":"Hansen, A. R. et al. Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study. Ann. Oncol. 29(8), 1807\u20131813 (2018).","journal-title":"Ann. Oncol."},{"issue":"5","key":"10724_CR16","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1200\/JCO.19.01638","volume":"38","author":"ES Antonarakis","year":"2020","unstructured":"Antonarakis, E. S. et al. Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 study. J. Clin. Oncol. 38(5), 395\u2013405 (2020).","journal-title":"J. Clin. Oncol."},{"key":"10724_CR17","unstructured":"Sweeney, C. J. et al. (eds). IMbassador250: a phase III trial comparing atezolizumab with enzalutamide vs enzalutamide alone in patients with metastatic castration-resistant prostate cancer (mCRPC). In: AACR annual meeting; 2020 April 27\u201328, 2020 and June 22\u201324, 2020; Philadelphia, PA (2020)."},{"key":"10724_CR18","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.semcancer.2020.07.004","volume":"71","author":"B Ma","year":"2021","unstructured":"Ma, B., Wells, A., Wei, L. & Zheng, J. Prostate cancer liver metastasis: dormancy and resistance to therapy. Semin. Cancer Biol. 71, 2\u20139 (2021).","journal-title":"Semin. Cancer Biol."},{"key":"10724_CR19","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.semcancer.2020.06.003","volume":"71","author":"AT Ciner","year":"2020","unstructured":"Ciner, A. T., Jones, K., Muschel, R. J. & Brodt, P. The unique immune microenvironment of liver metastases: challenges and opportunities. Semin. Cancer Biol. 71, 143\u2013156 (2020).","journal-title":"Semin. Cancer Biol."},{"issue":"19","key":"10724_CR20","doi-asserted-by":"publisher","first-page":"7304","DOI":"10.3390\/ijms21197304","volume":"21","author":"D Korentzelos","year":"2020","unstructured":"Korentzelos, D., Clark, A. M. & Wells, A. A perspective on therapeutic pan-resistance in metastatic cancer. Int. J. Mol. Sci. 21(19), 7304 (2020).","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10724_CR21","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s10585-011-9427-3","volume":"29","author":"Y Chao","year":"2012","unstructured":"Chao, Y., Wu, Q., Shepard, C. & Wells, A. Hepatocyte induced re-expression of E-cadherin in breast and prostate cancer cells increases chemoresistance. Clin. Exp. Metastasis 29(1), 39\u201350 (2012).","journal-title":"Clin. Exp. Metastasis"},{"issue":"1","key":"10724_CR22","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s12307-011-0085-4","volume":"5","author":"Y Chao","year":"2012","unstructured":"Chao, Y. et al. Partial mesenchymal to epithelial reverting transition in breast and prostate cancer metastases. Cancer Microenviron. 5(1), 19\u201328 (2012).","journal-title":"Cancer Microenviron."},{"issue":"6","key":"10724_CR23","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s10585-008-9167-1","volume":"25","author":"A Wells","year":"2008","unstructured":"Wells, A., Yates, C. & Shepard, C. R. E-cadherin as an indicator of mesenchymal to epithelial reverting transitions during the metastatic seeding of disseminated carcinomas. Clin. Exp. Metastasis 25(6), 621\u2013628 (2008).","journal-title":"Clin. Exp. Metastasis"},{"issue":"16","key":"10724_CR24","doi-asserted-by":"publisher","first-page":"11153","DOI":"10.1074\/jbc.M113.540237","volume":"289","author":"B Ma","year":"2014","unstructured":"Ma, B. & Wells, A. The mitogen-activated protein (MAP) kinases p38 and extracellular signal-regulated kinase (ERK) are involved in hepatocyte-mediated phenotypic switching in prostate cancer cells. J. Biol. Chem. 289(16), 11153\u201311161 (2014).","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10724_CR25","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1002\/hep.28755","volume":"64","author":"B Ma","year":"2016","unstructured":"Ma, B. et al. Liver protects metastatic prostate cancer from induced death by activating E-cadherin signaling. Hepatology 64(5), 1725\u20131742 (2016).","journal-title":"Hepatology"},{"issue":"6","key":"10724_CR26","doi-asserted-by":"publisher","first-page":"e38441","DOI":"10.1371\/journal.pone.0038441","volume":"7","author":"D Smyth","year":"2012","unstructured":"Smyth, D., Leung, G., Fernando, M. & McKay, D. M. Reduced surface expression of epithelial E-cadherin evoked by interferon-gamma is Fyn kinase-dependent. PLoS One 7(6), e38441 (2012).","journal-title":"PLoS One"},{"issue":"6","key":"10724_CR27","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1158\/0008-5472.CAN-18-2207","volume":"79","author":"UG Lo","year":"2019","unstructured":"Lo, U. G. et al. IFNgamma-induced IFIT5 promotes epithelial-to-mesenchymal transition in prostate cancer via miRNA processing. Cancer Res. 79(6), 1098\u20131112 (2019).","journal-title":"Cancer Res."},{"issue":"3","key":"10724_CR28","doi-asserted-by":"publisher","first-page":"e002138","DOI":"10.1136\/jitc-2020-002138","volume":"9","author":"Y Sun","year":"2021","unstructured":"Sun, Y. et al. N-cadherin inhibitor creates a microenvironment that protect TILs from immune checkpoints and Treg cells. J. Immunother. Cancer. 9(3), e002138 (2021).","journal-title":"J. Immunother. Cancer."},{"issue":"20","key":"10724_CR29","doi-asserted-by":"publisher","first-page":"3548","DOI":"10.1016\/j.vaccine.2010.03.007","volume":"28","author":"M Martini","year":"2010","unstructured":"Martini, M. et al. IFN-gamma-mediated upmodulation of MHC class I expression activates tumor-specific immune response in a mouse model of prostate cancer. Vaccine 28(20), 3548\u20133557 (2010).","journal-title":"Vaccine"},{"issue":"8","key":"10724_CR30","doi-asserted-by":"publisher","first-page":"3447","DOI":"10.1158\/0008-5472.CAN-04-4316","volume":"65","author":"GP Dunn","year":"2005","unstructured":"Dunn, G. P., Sheehan, K. C., Old, L. J. & Schreiber, R. D. IFN unresponsiveness in LNCaP cells due to the lack of JAK1 gene expression. Cancer Res. 65(8), 3447\u20133453 (2005).","journal-title":"Cancer Res."},{"issue":"12","key":"10724_CR31","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1016\/j.celrep.2015.08.044","volume":"12","author":"Y Nagai","year":"2015","unstructured":"Nagai, Y. et al. Disabling of the erbB pathway followed by IFN-\u03b3 modifies phenotype and enhances genotoxic eradication of breast tumors. Cell Rep. 12(12), 2049\u20132059 (2015).","journal-title":"Cell Rep."},{"issue":"2","key":"10724_CR32","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s11011-012-9283-0","volume":"27","author":"HA Seifert","year":"2012","unstructured":"Seifert, H. A. et al. The spleen contributes to stroke induced neurodegeneration through interferon gamma signaling. Metab. Brain Dis. 27(2), 131\u2013141 (2012).","journal-title":"Metab. Brain Dis."},{"issue":"2","key":"10724_CR33","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/s41577-020-0390-6","volume":"21","author":"D Dersh","year":"2021","unstructured":"Dersh, D., Holly, J. & Yewdell, J. W. A few good peptides: MHC class I-based cancer immunosurveillance and immunoevasion. Nat. Rev. Immunol. 21(2), 116\u2013128 (2021).","journal-title":"Nat. Rev. Immunol."},{"issue":"12","key":"10724_CR34","doi-asserted-by":"publisher","first-page":"10284","DOI":"10.18632\/oncotarget.22888","volume":"9","author":"CD Fankhauser","year":"2018","unstructured":"Fankhauser, C. D. et al. Comprehensive immunohistochemical analysis of PD-L1 shows scarce expression in castration-resistant prostate cancer. Oncotarget 9(12), 10284\u201310293 (2018).","journal-title":"Oncotarget"},{"issue":"2","key":"10724_CR35","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.ccell.2019.06.008","volume":"36","author":"HH Lee","year":"2019","unstructured":"Lee, H. H. et al. Removal of N-linked glycosylation enhances PD-L1 detection and predicts anti-PD-1\/PD-L1 therapeutic efficacy. Cancer Cell. 36(2), 168-178 e164 (2019).","journal-title":"Cancer Cell."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-10724-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-10724-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-10724-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T20:47:04Z","timestamp":1669322824000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-10724-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,22]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["10724"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-10724-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.08.20.457028","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,22]]},"assertion":[{"value":"16 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6657"}}